Evidence map›Paper›PMID 40514754›Full record

ReviewExperimental hematology & oncology2025

Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities.

Changjing Cai, Yiting Liu, Ruohuang Lu, Xudong Fan, Shan Zeng, Pingping Gan

Abstract readReview
In one paragraph

Review in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Complement system in tumor growth and metastases.British journal of cancer · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Changjing Cai *Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Yiting Liu *Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Ruohuang LuDepartment of Stomatology, the Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xudong FanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Shan ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Pingping GanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. gppxy@csu.edu.cn.

Funding

China Postdoctoral Science Foundation 2024M753679Degree & Postgraduate Education Reform Project of Central South University 2024JGB121National Natural Science Foundation of China No.82274606National Natural Science Foundation of China No.82403920Natural Science Foundation of Hunan Province No.2023JJ30834Natural Science Foundation of Hunan Province No.2023JJ30876Natural Science Foundation of Hunan Province No.2024JJ6662Nature Science Foundation of Changsha No.kq2403008Postdoctoral Fellowship Program of the CPSF GZC20242044Science and Technology Innovation Program of Hunan Province No.2024RC3042Youth Science Foundation of Xiangya Hospital No.2023Q01
6 · The paper itself

Abstract

Platelets play a critical role in tumor immunity, particularly in promoting cancer progression. Numerous studies suggest that platelets could serve as a novel target for cancer immunotherapy, however, no comprehensive reviews have yet summarized and discussed this potential. Our review provides an in-depth discussion of the roles and mechanisms of platelets within both the immunosuppressive tumor microenvironment and the anti-tumor immune microenvironment. Additionally, we summarize the key therapeutic targets and approaches for clinical translation. This work offers essential insights for reprogramming platelets to shift their function from tumor promotion to tumor suppression, providing a foundation for the development of novel immunotherapeutic strategies and related research.

Indexed as

CancerImmunotherapyPlateletTumor microenvironment

Identifiers

PMID40514754
PMCPMC12166581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.